Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder  by Divekar, Abhay et al.
CC
S
A
M
M
T
o
p
A
I
T
C
n
i
M
C
c
h
o
e
C
o
e
k
c
d
§
t
2
Journal of the American College of Cardiology Vol. 45, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PLINICAL RESEARCH Percutaneous Closure of ASO
ardiac Perforation After Device Closure of Atrial
eptal Defects With the Amplatzer Septal Occluder
bhay Divekar, MBBS,* Tidimogo Gaamangwe, MSC, PENG,‡ Nasir Shaikh, MBBS,†
ichael Raabe, MD,§ John Ducas, MD†
anitoba, Canada
OBJECTIVES Amplatzer septal occluder (ASO)-associated cardiac perforation (CP) at our institution
prompted this retrospective review.
BACKGROUND Cardiac perforation is a rare complication after transcatheter atrial septal defect (ASD)
closure.
METHODS To identify CP after transcatheter ASD closure with ASO, cardiac events (CE) describing
definite CP, hemopericardium, pericardial effusion, cardiovascular collapse, or sudden death
were analyzed. Cardiac events were identified from published literature (MEDLINE),
medical device regulating agencies in North America and the European Commission, and
AGA Medical Corporation (Golden Valley, Minnesota). Institutional cases were reviewed.
Cardiac events were defined as early (pre-discharge) or late (post-discharge).
RESULTS Twenty-nine CEs were identified. Five were excluded because findings were inconclusive for
device-related CP. Ten patients were 18 years of age. Late CEs occurred in 66.6%; 25%
presented weeks later (longest, three years). Three deaths were reported. Cardiac perforation
occurred predominantly in the anterosuperior atrial walls and/or adjacent aorta.
CONCLUSIONS Amplatzer septal occluder-associated CP uniquely involves the anterosuperior atrial walls and
adjacent aorta. Pathophysiology remains poorly understood. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.0721213–8) © 2005 by the American College of Cardiology Foundation
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sranscatheter closure of atrial septal defect (ASD) is now
ffered as an acceptable alternative to surgery (1,2). Cardiac
erforation (CP) is a unique complication of transcatheter
SD and patent foramen ovale (PFO) closure (1,3–8).
ncidence varies from 0.1% to 4% for various devices (1,3).
he Amplatzer septal occluder (ASO) (AGA Medical
orp., Golden Valley, Minnesota) and implantation tech-
ique have been described. The ASO-associated CP at our
nstitution prompted retrospective review.
ETHODS
ase definition. To identify CP after transcatheter ASD
losure with ASO, cardiac events (CE) describing definite CP,
emopericardium, pericardial effusion, cardiovascular collapse,
r sudden death were analyzed. Cardiac events were defined as
arly (pre-discharge) or late (post-discharge).
ase identification. Retrospective review was conducted
f institutional cases including procedural transesophageal
chocardiography (TEE) and catheterization data.
A literature search was conducted via MEDLINE using
ey words: Amplatzer, Amplatzer septal occluder, compli-
ations, perforation, erosions, cardiovascular collapse, sud-
en death, and hemopericardium.
From the Sections of *Pediatric and †Adult Cardiology, ‡Clinical Engineering, and
Cardiovascular and Thoracic Surgery, Health Sciences Center, Winnipeg, Mani-
oba, Canada.l
Manuscript received October 23, 2004; revised manuscript received December 18,
004; accepted December 20, 2004.During review, ASO-associated CPs were identified from
he U.S. Food and Drug Administration (FDA) website
rompting a search of CEs reported to other medical device
egulating agencies in North America and the European
ommission (websites and/or direct communication).
ESULTS
nstitutional cases. A 24-year-old woman (case #29, 160
m, 40.8 kg; Table 1) was the 13th patient undergoing
evice closure in March 2002. An ASD measuring 15  17
m by TEE with a stretched balloon diameter (SBD) of 23
m and deficient anterosuperior rim was closed with a
6-mm ASO using fluoroscopy and TEE. The device
played over the aorta (Fig. 1); there was no residual shunt
r impingement on cardiac structures. She was discharged
he same evening on aspirin and clopidogrel. Chest radio-
raph was unremarkable. She was asymptomatic before
ollapse three days later. After cardiopulmonary resuscita-
ion, emergent surgical exploration found a hemopericar-
ium, and perforations were identified in the anterosuperior
ight atrial wall and the contiguous right posterior aortic
all. The device was removed, the ASD was closed, and the
erforations were repaired. Life support was withdrawn
hree days later secondary to irreversible neurologic insult.
ostmortem examination confirmed intraoperative findings
Fig. 2). Guidewire/delivery catheter-related injury was
uggested, citing atraumatic rounded edge of the device and
ack of published complications.
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Cardiac Perforation After Device Closure With ASO April 19, 2005:1213–8A 42-year-old woman (case #8, 160 cm, 56 kg; Table 1)
as the 23rd patient undergoing closure. An ASD, mea-
uring 10 mm  13 mm by TEE with a 17-mm SBD and
dequate rims was closed with a 20-mm ASO using
uoroscopy and TEE. There was no residual shunt, im-
ingement on cardiac structures, or splaying over the aorta
Fig. 1). Aspirin and clopidogrel were prescribed. Hospital
olicy after this incident resulted in hospitalization for three
ays. Echocardiogram 24 h later showed good device
osition and no effusion. Three days later chest pain and
hortness of breath were associated with an expanding
ffusion. Emergent surgical exploration found a hemoperi-
ardium, and the rim of the device was eroding through the
trial perforation. Anterosuperior right and left atrial per-
orations were noted at the edge of the respective retention
isks (Fig. 3). The device was removed, the ASD was
losed, and the perforations were repaired. Recovery was
neventful.
In both patients device integrity was maintained.
igure 1. Transesophageal echocardiogram showing (A) device splayed
Abbreviations and Acronyms
ASD  atrial septal defect
ASO  Amplatzer septal occluder
CE  cardiac events
CP  cardiac perforation
FDA  Food and Drug Administration
MAUDE  Manufacturer And User facility Device
Experience database
PFO  patent foramen ovale
SBD  stretched balloon diameter
TEE  transesophageal echocardiographya
ver aortic root and (B) device without splaying over the aortic root. AO
aorta; ASO  Amplatzer septal occluder; RA  right atrium.nalysis of reported cases. All cases reported to the
anufacturer and regulating agencies and published in the
iterature have been accounted for and reported only once
Table 1). The U.S. FDA and Health Canada were the only
gencies who had received reports of CP (Table 2). Only the
.S. FDA had free and easily accessible online information
ia the Manufacturer And User facility Device Experience
MAUDE) database.
Twenty-nine CEs were identified. Five were excluded
ecause findings were inconclusive for device-related CP.
ll patients presented with chest pain, shortness of breath,
emodynamic collapse, or sudden death. Ten patients were
18 years of age, and 76% were women.
Among the remaining 24 CEs, 14 had defined CP and
emopericardium, 3 had defined CP and fistula formation,
nd 5 had hemopericardium only. The ASO size ranged
rom 12 to 38 mm. Relationship between SBD and ASO
ize is shown in Table 3. Device malposition or breach in
tructural integrity was not reported. Information regarding
SD morphology and technical details was not consistently
vailable.
The CEs occurred early in 20.8% and late in 66.6%
unknown in three patients). The CEs presented 1.5 h to 3
ears after intervention: 5 within 1 day, 10 within 3 days,
nd 6 after 3 days (3 weeks to 3 years). Good outcome was
eported in 14 patients; 3 patients had neurological deficits,
igure 2. Postmortem illustration shows the atrial septum through the
pened right atrium. The surgically closed ASD is seen (open arrow).
robe shows site of right atrial perforation at the edge of the retention disk
ith and without device superimposition (closed arrows). ASD  atrial
eptal defect; ASO  Amplatzer septal occluder; RAA  right atrial
ppendage; TV  tricuspid valve.nd 3 patients died (unknown in 4 patients).
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April 19, 2005:1213–8 Cardiac Perforation After Device Closure With ASOSites of CP are shown in Table 4. All CP (except case #4)
ccurred in the anterosuperior atrial walls and/or adjacent
orta. All patients with CP and hemopericardium had
ardiac tamponade; pericardiocentesis was performed in 10
atients. Surgical exploration was performed in 19 of 24
atients. The ASO was explanted in 15 patients and
emains implanted in 7 patients (no recurrences reported).
Recent registry review suggests device oversizing and
eficient anterosuperior rims as risk factors for CP and
ecommends abolishing intentional oversizing, stop-flow
ethod for SBD, and careful follow-up of “high-risk”
ases (1).
ISCUSSION
echnique-related CP during catheterization is inherent to
he procedure, typically occurs before hospital discharge and
s amenable to intervention. In contrast, device-related CP
ccurs after a technically adequate procedure, frequently
fter hospital discharge (66.6% in this review), and has the
otential for a fatal outcome (1).
The rounded design and flexibility of the ASO is specu-
ated to minimize risk of CP, even when oversized (2). An
cclusion device within confines of the anteroposterior
eptal length is subjected to deformation forces (9). Fatigue
ractures are not reported with the ASO, and the disks
igure 3. Intraoperative illustration shows the atrial septum through the
pened right atrium before and after explanting the ASO. The right atrial
erforation occurs at the edge of the retention disk (white arrow). AO 
orta; ASD  atrial septal defect; ASO  Amplatzer septal occluder.etain preformed shape; we therefore hypothesize that the tSO transmits deformative forces to the tissues at the point
f contact between the aorta, the device, and the anterosu-
erior atrial walls resulting in CP.
This review shows that the anterosuperior atrial walls
nd/or adjacent aorta are uniquely vulnerable, the side of the
arger ASO disk does not predict site of CP (Table 4),
rauma over multiple cardiac cycles can damage even the
hicker, more resilient aortic wall, and larger devices are not
isproportionately represented (13 devices 25 mm, 11
evices 25 mm) in patients with CP. The CP associated
ith other devices also involves the free/anterosuperior
trial walls and/or adjacent aorta (3,4).
Closure of ASDs with deficient anterosuperior rims and
bility to intentionally oversize by splaying over the aorta are
mong published merits of the ASO (2). Registry review
ow suggests otherwise (1). Comparison among patients
eceiving intentionally oversized ASOs with and without
omplications is necessary. Registry recommendations, al-
hough important, need validation. Several points deserve
crutiny. First, CP developed in registry patients (10 of 28)
ith devices sized equal to the SBD (1). Second, CP did not
evelop in all patients receiving intentionally oversized
evices (2). Third, recurrences are not reported in patients
n whom CP developed where devices remain implanted.
orth, unpredictable timing for developing CP makes care-
ul follow-up difficult.
All postmortem reports concluded CP to be non–device-
elated. With information now available, we believe that our
atient clearly had device-related CP. It is possible that
ases #27 and #28 (Table 1) with unexplained fresh blood in
he pericardial sac, may now be seen in a different light.
Prior to November 2004, there are three reports of
SO-associated perforation or fistula formation (5–7).
uring the same interval, the MAUDE database reports
everal cases. Therefore, physicians should be aware of and
tilize resources other than traditional literature. Ideally an
nternational registry and periodic end-user notification is
ecessary.
tudy limitations. We acknowledge the limitations of this
etrospective review. The MAUDE database is not in-
ended for this purpose. The study was not designed for
tatistical analysis or causation but focuses on a poorly
nderstood complication.
Informed consent should highlight device-related CP.
ymptoms consistent with CP warrant prompt evaluation
ncluding urgent echocardiography. Widespread awareness
ay allow for timely recognition. Prompt pericardiocentesis
efore surgical exploration may minimize morbidity and
ortality. Device removal should be considered in patients
resenting with CP. Occluder size relative to anteroposte-
ior septal dimension may be important and needs to be
tudied.
Understanding the pathophysiology of CP is crucial to
he ongoing success of transcatheter therapy.
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
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Cardiac Perforation After Device Closure With ASO April 19, 2005:1213–8able 1. Details of Cardiac Events From MAUDE Database
Case
No. IP/OP
Device
Size
(mm)
Stretched
Balloon
Diameter
Timing of Event
After Procedure
Interval
ECHO Presenting Symptoms Site of Perforation
1 ND 38 NR 2 days (30 h) ND Tamponade ND
2 ND 28 NR 1 day (22 h) ND Tamponade and collapse Ao
3 ND 34 NR ND ND Chest pain and tamponade LA
4 IP 18 NR 1 day (1 1/2 h) ND Cardiac arrest Multiple LA
5 IP 24 NR 2 days ND Chest pain RA and Ao
6 IP 20 NR 1 day (3 h) ND Hypotension RA and Ao
7 IP 14 12 2 days ND Pre-tamponade ND
8 IP 20 17 3 days P Chest pain and SOB RA and LA
9 IP 36 NR 4 h NP Hypotension, tachycardia, shock Right upper pulmonary
vein
10 IP 34 NR 2 h NP Chest pain NA
11 OP 19 20 ND ND SOB, shock NA
12 OP 22 NR 6 days P Sudden death ND
13 OP 22 NR 1 month P Vasovagal discomfort Posterior wall of LA
14 OP 12 NR 2 days P Nausea vomiting pallor, hypotension,
and tachycardia
RA
15 OP 22 NR 2 months ND Chest pain LA
16 OP 18 NR 2 days (40 h) P Chest pain, dizziness, collapse RA, Ao
17 OP 17 17 1 day ND Chest pain, nausea, and vomiting LA, Ao
18 OP 26 NR ND P Chest pain and syncope LA
19 OP 24 NR 3 yrs ND Cardiac tamponade, CVA Suspected erosion of
Ao
20 OP 14 NR 6 months ND Acidosis, low output, tamponade LA
21 OP 20 NR ND P Chest pain syncope RA
22 OP 28 NR 1 day (24 h) ND Chest pain, SOB, hypotension ND
23 OP 16 NR 2 days P Nausea, restless, and questionable
respiratory arrest
ND
24 OP 30 NR 6 months P Asymptomatic Ao to LA fistula
25 OP 26 26 3 months P Asymptomatic Ao to RA fistula
26 OP 26 25–26 3 weeks ND Hemolysis Ao to LA fistula
27 OP 26 NR 2 days ND Chest discomfort, SOB, while doing
homework, collapse
None
28 OP 26 NR 2 days ND Chest pain, SOB collapse, had a
negative Holter, no history of
palpitations
None
29 OP 26 23 3 days NP Collapsed in parking lot RA, Ao
ases in italics were excluded from analysis.
Ao  aorta; ECHO  echocardiogram; I  device remains implanted; IP  inpatient; LA  left atrium; NA  not applicable; ND  no data; NP  not performed; NR
not reported; NSAIDS  non-steroidal anti-inflammatory drugs; OP  outpatient; P  interval echo performed, no effusion, no residual shunt, stable device position, no
stula seen; R  device removed; RA  right atrium; SOB  shortness of breath.
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April 19, 2005:1213–8 Cardiac Perforation After Device Closure With ASOable 1 Continued
Tamponade Hemopericardium Pericardiocentesis
Device
Implanted/Removed Comments Outcome
Y ND ND R Device looked very large and was still left behind,
underwent surgery
Good
Y Y Y R Underwent surgery Good
Y Y Y R Technically difficult procedure, underwent surgery ND
Y Y N I Multiple laceration secondary to aggressive CPR,
underwent surgical repair of lacerations
Neuro insult
Y Y N R Underwent surgery ND
Y Y Y R Underwent surgery Good
Pre-tamponade Y Y I Drained, hospitalized for 10 days, no
reaccumulation, no surgery
Good
Y Y N R Monitored in hospital because of previous
experience, underwent surgery
Good
Y Y N NA The sizing balloon/guidewire likely caused
perforation during manipulation for balloon
sizing
Death
N ND N I Stable 8-mm effusion, treated with oral NSAIDS,
no surgery
Good
Y N Y I Serous fluid, treated as pericarditis, conservative
management, no surgery
Good
ND ND ND NA Sudden death reported, no other details were
available, no surgery
Death
Y Y N I Car accident, hemopericardium 6 h later, underwent
surgery
Good
Y Y N R Emergent surgery Good
Y Y Y I Erosion of strut, underwent surgery ND
Y Y Y R Underwent surgery Neuro insult
Y Y N R Insufficient superior rim, good device position,
underwent surgery
Good
Y Y Y R Underwent surgery Good
Y Y Y I Surgery delayed because of stroke, erosion
suspected by AGA Medical, surgery was
recommended
Neuro insult
Y Y N I Underwent surgery, buttress to the retroaortic
atrial wall provided
Good
Y Y N R Underwent surgery ND
Y ND Y I Only underwent subxiphoid exploration, no blood
seen, no intervention
Good
Y Y Y I Drained 2 days, no reaccumulation, discharged on
NSAIDS, no surgery
Good
NA NA NA R Initially 28 mm and then 30 mm device,
questionable abrasion during initial attempt,
however, no fistula at 1 month, underwent
surgery
Good
NA NA NA R Device flared around aorta, RA disk concave at
time of surgery, underwent surgery
Good
NA NA NA R Hemolysis, underwent surgery Good
Y Y N NA Preliminary autopsy no cause of death, fresh
blood in pericardium and left pleura
Death
Y Y N NA Sufficient rims, arrhythmia-related death on
preliminary autopsy, fresh blood found in
pericardium and left pleura
Death
Y Y N R Patient underwent surgery but brain death 3 days
later
Death
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